Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. doi: 10.1016/j.clml.2014.06.004. Epub 2014 Jun 11.

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Author information

  • 1Willamette Valley Cancer Institute, Eugene, OR. Electronic address: Jeff.Sharman@USOncology.com.
  • 2Foundation Medicine Inc, Cambridge, MA.
  • 3Foundation Medicine Inc, Cambridge, MA; Albany Medical College, Albany, NY.
  • 4Willamette Valley Cancer Institute, Eugene, OR.

KEYWORDS:

Mitogen-activated protein kinase; Mutation; Refractory myeloma; V600E; Vemurafenib

PMID:
24997557
DOI:
10.1016/j.clml.2014.06.004
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center